Company news

MediWound Ltd. news in 2024

MediWound Ltd.'s news releases, calls and decks from 2024, newest first.

View company

MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025

December 16, 2024

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

November 25, 2024

MediWound to Report Third Quarter 2024 Financial Results

November 11, 2024

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

October 9, 2024

MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

October 7, 2024

MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

August 14, 2024

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

August 13, 2024

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

August 4, 2024

MediWound to Report Second Quarter 2024 Financial Results

August 1, 2024

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

July 28, 2024

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

July 15, 2024

MediWound Announces $25 Million Strategic Private Placement Financing

July 14, 2024

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 28, 2024

MediWound to Report First Quarter 2024 Financial Results

May 21, 2024

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

April 24, 2024

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 20, 2024

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

February 11, 2024

MediWound to Participate in Two Upcoming Investor Conferences

February 4, 2024

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

January 8, 2024

Calls in 2024

Decks in 2024